Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2021, with a specific transaction date of May 24, 2021. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $38.6700 |
| Volume | 1,197.404 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single acquisition event within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Executive Action: Dr. H. Barron, Chief Scientific Officer and President, R&D, acquired 1,197.404 notional ADSs.
- Transaction Date: May 24, 2021.
- Transaction Price: $38.67 per ADS.
- Context: The acquisition was part of an executive supplemental savings plan, not an open market trade by the executive for personal discretionary purposes.
- Financial Data: This filing does not contain quarterly or annual financial results.